# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-046860
Filing Date
2022-04-18
Accepted
2022-04-18 16:11:07
Documents
4
Period of Report
2022-06-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm223565d1_def14a.htm | DEF 14A | 260394
2 | GRAPHIC | tm223565d1_def14asp1img001.jpg | GRAPHIC | 5762
3 | GRAPHIC | tm223565d1_def14aimg002.jpg | GRAPHIC | 133151
4 | GRAPHIC | tm223565d1_def14aimg003.jpg | GRAPHIC | 508033
| Complete submission text file | 0001104659-22-046860.txt |  | 1153013

Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39202 | Film No.: 22832265
SIC: 2834 Pharmaceutical Preparations